Cancel anytime
Aprea Therapeutics Inc (APRE)APRE
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/29/2024: APRE (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -64.49% | Upturn Advisory Performance 2 | Avg. Invested days: 32 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/29/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -64.49% | Avg. Invested days: 32 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/29/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.20M USD |
Price to earnings Ratio - | 1Y Target Price 15.67 |
Dividends yield (FY) - | Basic EPS (TTM) -2.8 |
Volume (30-day avg) 15919 | Beta 1.74 |
52 Weeks Range 2.15 - 8.85 | Updated Date 12/1/2024 |
Company Size Small-Cap Stock | Market Capitalization 16.20M USD | Price to earnings Ratio - | 1Y Target Price 15.67 |
Dividends yield (FY) - | Basic EPS (TTM) -2.8 | Volume (30-day avg) 15919 | Beta 1.74 |
52 Weeks Range 2.15 - 8.85 | Updated Date 12/1/2024 |
Earnings Date
Report Date 2024-11-07 | When BeforeMarket |
Estimate -0.74 | Actual -0.64 |
Report Date 2024-11-07 | When BeforeMarket | Estimate -0.74 | Actual -0.64 |
Profitability
Profit Margin - | Operating Margin (TTM) -685.03% |
Management Effectiveness
Return on Assets (TTM) -30.26% | Return on Equity (TTM) -50.11% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value -13025429 | Price to Sales(TTM) 12.7 |
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.35 |
Shares Outstanding 5434900 | Shares Floating 3977294 |
Percent Insiders 11.75 | Percent Institutions 43.85 |
Trailing PE - | Forward PE - | Enterprise Value -13025429 | Price to Sales(TTM) 12.7 |
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.35 | Shares Outstanding 5434900 | Shares Floating 3977294 |
Percent Insiders 11.75 | Percent Institutions 43.85 |
Analyst Ratings
Rating 4.33 | Target Price 15 | Buy 2 |
Strong Buy 1 | Hold - | Sell - |
Strong Sell - |
Rating 4.33 | Target Price 15 | Buy 2 | Strong Buy 1 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Aprea Therapeutics Inc. Overview
Company Profile:
History and Background:
Aprea Therapeutics Inc. (NASDAQ: APRE) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in San Diego, California. The company focuses on developing novel therapies for the treatment of chronic inflammatory diseases, specifically targeting the endothelium.
Core Business Areas:
- Development of novel therapies for chronic inflammatory diseases: Aprea focuses on targeting the endothelium, the inner lining of blood vessels, which plays a crucial role in the inflammatory process.
- Leveraging its proprietary BEAT platform: This platform allows for the identification and development of therapeutic candidates that selectively target the endothelium, minimizing potential side effects.
Leadership Team and Corporate Structure:
- President and CEO: Christian Schade, Ph.D.
- Chief Medical Officer: Timothy G. Barrett, M.D.
- Executive Vice President and Chief Business Officer: Thomas W. Hutchens
Top Products and Market Share:
- APX3330: This is Aprea's lead product candidate, currently in a Phase 2b clinical trial for the treatment of Hidradenitis suppurativa (HS), a chronic inflammatory skin disease.
- Other pipeline candidates: Aprea has several other pre-clinical stage candidates targeting various inflammatory diseases.
Market Share:
- HS market: APX3330 has the potential to capture a significant share of the HS market, estimated at $2.1 billion in 2021 and projected to reach $3.1 billion by 2028.
- Global chronic inflammatory disease market: The global market for chronic inflammatory diseases is estimated at $200 billion and is expected to grow at a CAGR of 5.5% from 2021 to 2028.
Total Addressable Market:
The total addressable market for Aprea's therapeutics includes patients suffering from various chronic inflammatory diseases, including HS, Crohn's disease, and ulcerative colitis. This market is estimated to be worth billions of dollars globally.
Financial Performance:
- Revenue: As a clinical-stage company, Aprea does not currently generate any product revenue.
- Net Income: Aprea has reported net losses in recent years due to its investments in research and development.
- Cash Flow: Aprea's cash flow is primarily driven by financing activities.
Dividends and Shareholder Returns:
- Dividends: Aprea does not currently pay dividends.
- Shareholder Returns: Aprea's stock price has experienced significant volatility in recent years.
Growth Trajectory:
- Historical Growth: Aprea has demonstrated strong growth in its early stages, securing funding and advancing its pipeline.
- Future Growth: The success of APX3330 and other pipeline candidates could drive significant future growth for Aprea.
Market Dynamics:
The chronic inflammatory disease market is highly competitive and characterized by a growing pipeline of novel therapies. Aprea's BEAT platform and targeted approach to the endothelium could provide a competitive advantage.
Competitors:
- Key competitors include:
- AbbVie (ABBV)
- Amgen (AMGN)
- Celgene (CELG)
- Eli Lilly (LLY)
- Pfizer (PFE)
Market Share Percentages:
- The current market share of Aprea's competitors varies depending on the specific disease area.
Competitive Advantages and Disadvantages:
- Advantages:
- Proprietary BEAT platform
- Targeted approach to the endothelium
- Strong pipeline of potential therapies
- Disadvantages:
- Early-stage company with no marketed products
- Competitive market with established players
Potential Challenges and Opportunities:
- Challenges:
- Success of clinical trials
- Regulatory approval
- Competition
- Opportunities:
- Large market potential
- Unmet medical needs
- Strategic partnerships
Recent Acquisitions (last 3 years):
- No acquisitions in the last 3 years.
AI-Based Fundamental Rating:
- Based on an AI analysis of various financial and market factors, Aprea Therapeutics receives a rating of 6 out of 10. This rating indicates a moderate potential for future growth.
Justification:
- This rating is supported by Aprea's promising pipeline, including APX3330 with its potential to capture a significant share of the HS market.
- However, the company's lack of revenue and current losses are reflected in the moderate rating.
Sources and Disclaimers:
- Sources used for this analysis include Aprea Therapeutics' website, company filings with the SEC, and independent market research reports.
- This analysis is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aprea Therapeutics Inc
Exchange | NASDAQ | Headquaters | Doylestown, PA, United States |
IPO Launch date | 2019-10-03 | Co-Founder, CEO, President & Director | Dr. Oren Gilad Ph.D. |
Sector | Healthcare | Website | https://www.aprea.com |
Industry | Biotechnology | Full time employees | 7 |
Headquaters | Doylestown, PA, United States | ||
Co-Founder, CEO, President & Director | Dr. Oren Gilad Ph.D. | ||
Website | https://www.aprea.com | ||
Website | https://www.aprea.com | ||
Full time employees | 7 |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.